Global Dtp Vaccines Market

The vaccines market consists of sales of vaccines and related services. This industry includes establishments that produce anti-infective vaccines, autoimmunity vaccines and vaccines for cancer and other diseases. Vaccines create antibody-antigen reaction that helps in attaining resistance to the disease causing organism. Vaccines include recombinant vaccines, conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines and others. The market covered in the vaccines market report is segmented by type into anti-infective vaccines, autoimmunity, others (cancer and others); by technology into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines; by route of administration into intramuscular (IM), subcutaneous (SC), oral, others; by valance into monovalent, multivalent; by distribution channel into institutional sale, hospital pharmacies, retail pharmacies. The global vaccines market is expected to decline from $56.02 billion in 2020 to $55.97 billion in 2021 at a compound annual growth rate (CAGR) of -0.1%. The slow decline is mainly due to the outbreak of COVID-19 that has led to deferment of immunocompromised treatments. The vaccines market is expected to reach $85.93 billion in 2025 at a CAGR of 11.3%. Rising awareness on immunization and vaccination benefits in emerging markets is consistently driving the global vaccines market growth. World Health Organization (WHO) is taking initiatives to increase awareness of immunization through global vaccine action plan (GVAP) and global Immunization vision and strategy (GIVS). They aim to strengthen routine immunization, control morbidity and mortality from vaccine preventable diseases and help countries to immunize more people with a greater range of vaccines. The Organization accomplishes this work through its biological programme, the WHO Collaborating Centers, and the WHO Expert Committee on Biological Standardization (ECBS). In 2019, according to the WHO, approximately 85% of infants globally (116 million infants) received 3 doses of diphtheria-tetanus-pertussis (DTP3) vaccine, protecting them against infectious diseases that can cause serious illness and disability or be fatal. Furthermore, 125 countries reached at least 90% coverage of the DTP3 vaccine in 2019. The vaccines market growth is limited due to severe shortage of skilled healthcare professionals for developing biologics drugs which requires specialized skillsets. These skillsets are limited to some research organizations and medical equipment companies in the USA and Europe, this is expected to be a major restraint on the market. As of 2018, 40% of the biopharma industry was facing difficulties in hiring for process development staff due to shortage of talent. This shortage also led to rise in competition and salaries for the limited talent pool available for biologics talent, thereby further limiting growth of the market. The vaccines market has been witnessing multiple strategic initiatives and mergers and acquisitions in the recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden products and services. For instance, in February 2019, Bharat Biotech acquired Chiron Behring Vaccines, a clinical biotechnology company, one of the leading manufacturers of rabies vaccines across the globe. Similarly, in October 2018, Emergent BioSolutions, a multinational specialty biopharmaceutical company, acquired PaxVax for $270 million, and Sanofi acquired Protein Sciences for $650 million. Companies in the industry are increasingly realigning their portfolios and pursuing profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favourable interest rates globally. The Food and Drug Administration (FDA) is the National Regulatory Authority (NRA) in the United States responsible for assuring quality, safety, and effectiveness of all vaccines for human use. Center for Biologics Evaluation and Research (CBER) within the US FDA is responsible for regulating vaccines market. Governments across the world are encouraging the research and development of biologics in order to develop more targeted therapies and vaccines for various diseases. In May 2014, the US’s FDA announced a fast-track initiative to review its drugs and biologics policy to speed the availability of therapies to patients with serious conditions, orphan drugs for rare disease, while preserving the safety and efficacy standards. In 2016, FDA also removed a rule (Section 610.21 of the FDA code) which specified minimal potency limits for certain antibodies and antigens.. In addition, FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. In October 2018, Emergent BioSolutions, a multinational specialty biopharmaceutical company, acquired PaxVax for $270 million. This acquisition would strengthen and expand Emergent BioSolution's product portfolio with PaxVax's typhoid vaccine Vivotif, cholera vaccine Vaxchora and additional clinical-stage vaccine used in the prevention of typhoid fever, cholera, chikungunya and other emerging infectious diseases. PaxVax is a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious diseases. PaxVax was founded in 2006 and is headquartered in Cayman Islands, a British Overseas Territory. Major players in the vaccines market are AstraZeneca, Emergent Biosolutions, GlaxoSmithKline, Merck, and Pfizer Inc. The regions covered in the vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global vaccines market is segmented - 1) By Type: Anti-Infective Vaccines, Autoimmunity, Others (Cancer And Others) 2) By Technology: Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines 3) By Route of Administration: Intramuscular (IM), Subcutaneous (SC), Oral, Others 4) By Valance: Monovalent, Multivalent 5) By Distribution Channel: Institutional Sale, Hospital Pharmacies, Retail Pharmacies

The cancer vaccines market consists of sales of vaccines used for the treatment of cancers and related services by entities (organizations, sole traders and partnerships) that produce vaccines for cancer treatment. Cancer treatment vaccines, also called therapeutic vaccines are a type of immunotherapy, which stops tumor growth, destroys cancer cells and prevents the reoccurrence of cancers. The market consists of revenue generated by the company’s manufacturing cancer vaccines by the sales of these products. The cancer vaccines market covered in this report is segmented by type into preventive cancer vaccines, therapeutic cancer vaccines. The cancer vaccines market is also segmented by technology into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, viral vector & DNA cancer vaccines, by cancer type into prostate, cervical, colorectal, throat, others and by end-user into cancer treatment centers, research institutes. The global cancer vaccines market is expected to grow from $4.9 billion in 2020 to $5.55 billion in 2021 at a compound annual growth rate (CAGR) of 13.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer vaccines market is expected to reach $9.18 billion in 2025 at a CAGR of 13%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer vaccines market during the forecast period. According to the American Cancer Society, there were 1,7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the cancer vaccines market over the coming years. Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to have a negative impact on the revenues of cancer vaccines manufacturing companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source and developing nations are using the benefits of natural compounds for therapeutic purposes, which is affecting the cancer vaccine sales. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027. This trend is expected to continue during the forecast period and limit the demand for cancer vaccines. Companies in the cancer vaccines market are increasingly investing in preventive or prophylactic vaccines for cancer prevention. Prophylactic vaccines are designed to build immunity in a patient. A prophylactic or preventative vaccine involves introducing antigens into a person's body. According to the World Health Organization, cervical cancer was reported as the second-most common cancer in women with an estimation of 84% new cases worldwide. So far, there are 3 HPV vaccines currently present for the prophylaxis of cancers. Two among these will protect against both HPV 16 and HPV 18, which causes 70% of cervical cancer and the third vaccine prevents 3 more oncogenic HPV types, which further causes 20% of cervical cancers. These three vaccines include Gardasil and Gardasil9 by Merck and Cervarix by GSK. In April 2019, Bayer, through its investment arm Leaps by Bayer, has invested in a US-based biotechnology firm Khloris Biosciences, which is focused on developing prophylactic anti-cancer vaccines. In May 2020, Merck, a US-based pharmaceutical company, acquired Themis Bioscience for an undisclosed amount. The acquisition is expected to complement Merck's capabilities in the development, manufacturing, and distribution of vaccines. Themis Bioscience is a pharmaceutical company that manufactures vaccines and immune-modulatory therapies developed using the measles virus vector platform based on a vector originally. Major players in the cancer vaccines market are, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi Pasteur, Sanpower Group, and CSL Limited. The regions covered in the cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cancer vaccines market is segmented - 1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines 2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines 3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Others 4) By End-User: Cancer Treatment Centers, Research Institutes

The veterinary vaccines market consists of sales of vaccines and related services which are used for the treatment and prevention of diseases in animals. These veterinary vaccines reduce animal suffering and transmission of microorganisms in the animal population. Veterinary vaccines are used to enhance the immunity power of animals by improving the animal health, which also prevents transmission of diseases from animals to humans. Veterinary vaccines industry includes entities that produce veterinary vaccines like livestock vaccines and companion animal vaccines. The global veterinary vaccines market is expected to grow from $7 billion in 2020 to $7.73 billion in 2021 at a compound annual growth rate (CAGR) of 10.4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $10.18 billion in 2025 at a CAGR of 7.1%. The increase in the number of animals suffering from range of diseases is increasing the demand for vaccines to prevent and treat such diseases, thus driving the veterinary vaccines market According to the estimates from report by Animal and Plant Health Agency, a total of 3289 number of new TB herd incidents were detected in England Bovine tuberculosis is a chronic disease that usually affects animals such as cattle, but it can affect all mammals causing a general state of illness, coughing and eventually lead to death. However, the disease can be treated with specific antibiotics that kills the TB bacteria. This rising prevalence of diseases in animals is expected to drive the veterinary vaccines market during the forecast period. High storage costs are acting as a major restraint for the growth of the veterinary vaccine market. Improper storage conditions and delay in the shipping can cause vaccines to lose their desired immune properties. For example, during transportation, vaccines can undergo biodegradation, if they are not transported within the required temperature limits. Thus, special care is required for the transportation of the vaccines in order to maintain the efficiency of the vaccines, which increases the storage and transportation cost for the vaccines. According to report published by National Institute of Standards and Technology (NIST), approximately 35% of vaccines lost their potencies during the shipment, as they were stored at abnormal temperatures. Thus, high storage costs for vaccines are expected to result in additional costs for manufacturing companies and limit the growth of the market. Companies in the veterinary vaccines market are increasingly looking for strategic partnerships and collaborations to enter into new geographies and to share the Research & Development projects. For example, in 2020, the Pirbright Institute, a UK based animal disease research institute, partnered with ECO Animal Health, a UK based Pharmaceutical company, and the Vaccine Group (TVG) to develop porcine respiratory and reproductive syndrome virus (PRRSV) vaccines. The vaccine group is a biotechnology company that develops animal vaccines and is based in Plymouth, UK Similarly, MSD Animal Health, a division of Merck & Co with headquarters in the US, made a strategic partnership with Vinovo. This partnership will help MSD Animal Health to combine its unique broad vaccine product line and Vinovo’s vaccine delivery system to vaccination process, thus improving bird welfare, and reducing vaccine reactions. Also,Wageningen bio veterinary research made a strategic alliance Ceva with headquarters in Switzerland, to improve their Research on the global threat of emerging and reemerging diseases for animals. The veterinary vaccines market is regulated by authorities such as European Medical Agency and the US Center for Veterinary Biologics. For instance, veterinary vaccine companies in Europe are required to adhere to European technical requirements mentioned in Annex 1, Title II, to Directive 2001/82/EC, as amended by Directive 2009/9/EC, and the European Pharmacopoeia (Ph. Eur.). According to these regulations, veterinary vaccines are required to undergo safety test before getting the approval, where vaccines are classified into activated vaccines and inactivated Vaccines. In activated vaccines, each batch of vaccines should have a dose that is double the standard dose. In inactivated vaccines, each batch of vaccines should be ten times the standard dose for the active vaccines. Activated vaccines are usually tested by in vitro titration, while serological tests are commonly used for inactivated vaccines. Major players in the market are Boehringer Ingelheim GmbH, Merck Animal Health, Zoetis Inc., Eli Lilly and Company, and Bayer AG (Bayer Animal Health). The countries covered in the global veterinary vaccines market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global veterinary vaccines market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global veterinary vaccines market is segmented - 1) By Application: Livestock Vaccines, Companion Animal Vaccines 2) By Vaccine Type: Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Others 3) By Disease Type: Anaplasmosis, Canine Parvovirus, Foot & Mouth Disease, Newcastle Disease, Distemper Disease, Influenza, Porcine Reproductive & Respiratory Syndrome (PRRS)

The pediatric vaccines market consists of sales of pediatric vaccines and its related services used to provide immunity to infants and children for specific diseases. The pediatric vaccine is a preparation of killed microorganisms, living attenuated organisms, or living fully virulent organisms that are administered to stimulate the production of antibodies and provide immunity against one or several diseases among children. Pediatric vaccines are used in childhood immunization schedules to enhance a child’s immunity or prevent diseases such as diphtheria, tetanus, pertussis, influenza, Hepatitis B, polio, and many other infectious and non-infectious diseases. The global pediatric vaccine market is expected to grow from $28.97 billion in 2020 to $32.44 billion in 2021 at a compound annual growth rate (CAGR) of 12%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $49.9 billion in 2025 at a CAGR of 11.4%. The rising prevalence of chronic diseases such as tuberculosis, diphtheria, and pneumonia in the age group of 15 years and below will contribute to the growth of the pediatric vaccines market. The risk of severe disease outcomes and complications of infectious diseases are increasing in children and adolescents with chronic conditions. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. The increased prevalence of chronic diseases among children rises the demand for immunization from chronic diseases, hence, driving the pediatric vaccines market’s growth. Vaccine refusal by parents for their children is a prevailing tradition in many countries. Among the reasons for withholding children for vaccination are lack of knowledge, religious and philosophical objections, exaggerated concerns regarding vaccine safety, and others. According to a nationwide survey found that over half (51%) of pediatric services in the United States have the policy to dismiss families that refuse childhood vaccines. Thirty-seven percent of pediatricians themselves said they often dismissed families for refusing vaccines, and 6% said they would dismiss a family for choosing to reach out to crucial early vaccines. Governments are imposing laws and organizing awareness programs to overcome parent’s and family’s resistance to the child’s vaccine, but are unable to impose any strict rules against parents’ refusal for children’s immunization, which is hindering the pediatric vaccines market’s growth. The demand for novel vaccines is steadily growing to deliver improved immunization against challenging infectious diseases (e.g. tuberculosis, HIV/ AIDS) and non-communicable chronic diseases such as cancer and neurodegenerative diseases. Novel approaches to vaccine development include structural immunogenic design, gene-based vaccine platforms, and effective adjuvant recombinant antigen formulations. To meet the increasing demand for novel vaccines, there is a continuous quest for pediatric vaccine manufacturers and developers for innovation of vaccine design and manufacturing technologies. For instance, in January 2020, Hilleman laboratories, global research, and development organization, has announced their plans to develop a novel vaccine against Group B Streptococcus, a major cause for neonatal infections in women, in the area of maternal and child health. The major players covered in the global pediatric vaccine market are GlaxoSmithKline plc, Pfizer Inc., Sanofi S.A., Merck & Co., Inc., Indian Immunologicals Limited, AstraZeneca plc, CSL Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Panacea Biotec Ltd., Zydus Cadila, BIO-MED, Squibb, Novartis, Abbott Laboratries, Eli Lillyand Company, F. Hoffmann- La Roche Ltd., Novo Nordisk A/S, VF Corporation, Sinovac Biotech Ltd., Bristol- Myers, Sun Pharmaceutical Industries Ltd, Sellas and Takeda Pharmaceutical Company Limited, Daiichi Sankyo, Bristol- Myers, Sinovac Biotec Ltd. The countries covered in the global pediatric vaccine market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global pediatric vaccine market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global pediatric vaccine market is segmented - 1) By Vaccine Type: Monovalent, Multivalent 2) By Technology: Live Attenuated, Inactivated, Toxoid, Conjugate, Other Technologies 3) By Application: Infectious Disease, Allergy, Cancer

The pharmaceuticals market consists of sales of pharmaceuticals and related services by entities (organizations, sole traders and partnerships) that produce pharmaceuticals used in treating diseases. Pharmaceuticals can be any type of drugs that are used for medicinal purposes, in the treatment of diseases. This industry includes establishments that produce biologics and pharmaceutical drugs. The pharmaceuticals market is segmented into pharmaceutical drugs; and biologics. The global pharmaceuticals market is expected to grow from $1228.45 billion in 2020 to $1250.24 billion in 2021 at a compound annual growth rate (CAGR) of 1.8%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1700.97 billion in 2025 at a CAGR of 8%. North America was the largest region in the global pharmaceuticals market, accounting for 46% of the market in 2020. Asia Pacific was the second largest region, accounting for 26% of the global pharmaceuticals market. Africa was the smallest region in the global pharmaceuticals market. The population profile of most countries is becoming older. According to the Population Reference Bureau, the share of population over the age of 65 in the global population increased from 8% in 2015 to 9% in 2019. The global population aged 65 years or over was 703 million in 2019. This rise in the aging population increased the patient pool of many chronic diseases such as rheumatoid arthritis, hypertension, diabetes and cancer. The increase in the patient pool drove the demand for pharmaceuticals used in the treatment of these diseases, significantly impacting market growth during this period. The biologics market growth was limited due to severe shortage of skilled workforce for developing biologics drugs which require specialized skillsets. These skillsets are limited to some research organizations and medical equipment companies in the USA and Europe. As of 2018, 40% of the biopharma industry was facing difficulties in hiring for process development staff due to shortage of talent. This shortage led to rise in competition and salaries for the limited talent pool available for biologics manufacturing, thereby limiting growth of the market during the historic period. Pharmaceutical companies are offering drugs for customized individual treatment for various diseases. Personalized medicine, also referred to as precision medicine, aims to provide medical care according to the patient’s individual characteristics and genetic makeup. Precision therapies are increasingly being adopted as firms increasingly let go of the one-size-fits-all model for common medical conditions. Major companies such as GSK, Teva Pharmaceuticals and AstraZeneca are investing in development of personalized medicines. The major players covered in the global pharmaceuticals market are Pfizer, F. Hoffmann-La Roche Ltd, Sanofi, Johnson & Johnson, Merck & Co. The countries covered in the global pharmaceuticals market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam. The regions covered in the global pharmaceuticals market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global pharmaceuticals market is segmented - 1) By Type: Pharmaceutical Drugs, Biologics 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route Of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs Subsegments Covered: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs, Monoclonal Antibodies (MAbs), Therapeutic Proteins, Vaccines

The veterinary healthcare market consists sales of veterinary healthcare goods and services by entities (organizations, sole traders and partnerships) associated with diagnosis, treatment and prevention of diseases in animals. This industry includes establishments that provide veterinary services, veterinary medical equipment producers and animal medicine producers. The veterinary healthcare market is segmented into veterinary services; veterinary medical equipment and animal medicine. The global veterinary healthcare market is expected to grow from $127.69 billion in 2020 to $147.18 billion in 2021 at a compound annual growth rate (CAGR) of 15.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $182.68 billion in 2025 at a CAGR of 6%. North America was the largest region in the global veterinary healthcare market, accounting for 53% of the market in 2020. Western Europe was the second largest region, accounting for 21% of the global veterinary healthcare market. Africa was the smallest region in the global veterinary healthcare market. The global meat production is expected to rise in the forecast period, supporting the growth of the veterinary healthcare market. According to the US Department of Agriculture, in 2020, the beef production in the USA is expected to increase to 27.5 billion pounds, the highest production volume registered in the country. The rising meat production is especially prominent in developing countries such as China, India and Brazil, where increasing population and rising income levels are stimulating the demand for meat products. By 2027, the production of meat and poultry in emerging markets is expected to increase by 76%. By 2050, China's meat imports are expected to grow over 3,500% to $150 billion as consumption of chicken, pork and beef will surge due to the country's rising middle class. The rising production of meat products supported by growing population will increase the demand for feed additives in the livestock industry, driving the veterinary healthcare market. The outbreak of the Coronavirus disease (COVID-19) has acted as a massive restraint on the veterinary healthcare market in 2020 as supply chains were disrupted due to trade restrictions and consumption declined due to lockdowns imposed by governments globally. COVID 19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China and spread globally including Western Europe, North America and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of lockdown and the outbreak is expected to continue to have a negative impact on businesses throughout 2020 and into 2021. However, it is expected that the veterinary healthcare market will recover from the shock across the forecast period as it is a 'black swan' event and not related to ongoing or fundamental weaknesses in the market or the global economy. Nanotechnology is increasingly gaining traction in the animal medicine market as a substitute of veterinary antibiotics to tackle antibiotic resistance. Nanotechnology is the study of the controlling matter on an atomic and molecular scale. Nanotechnology in the animal medicine industry is used to improve diagnosis, treatment, animal growth promotion, and production. Nanoparticles are mainly used as alternative antimicrobial agents to reduce the use of antibiotics and improve the detection of pathogenic bacteria. They are also used as drug delivery agents for new drugs and vaccines candidates to improve their characteristics and performance, and to reduce drug resistance in animal organisms. The major players covered in the global veterinary healthcare market are Bayer AG, Boehringer Ingelheim GmbH, Cargill Inc., Ceva Santé Animale, Eli Lilly and Company. The countries covered in the global veterinary healthcare market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam. The regions covered in the global veterinary healthcare market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global veterinary healthcare market is segmented - 1) By Type: Veterinary Services, Veterinary Medical Equipment, Animal Medicine 2) By Type of Animal: Livestock, Companion Animals Subsegments Covered: Animal Hospitals And Veterinary Clinics, Veterinary Laboratory Testing Services, Veterinary Diagnostic Equipment, Veterinary Anesthesia Equipment, Veterinary Patient Monitoring Equipment, Other Veterinary Medical Equipment, Veterinary Pharmaceuticals, Feed Additives